Tag Archives: Warren Woessner

Fed. Cir.: Antitrust Issues Can Arise From Hatch-Waxman Litigation

Posted on August 7, 2014 by Warren Woessner

In Tyco Healthcare Group v. Mutual Pharm. Co., App. no. 13-1386 (Fed. Cir. August 6, 2014), a divided panel of the court reversed a district court’s summary judgment ruling dismissing antitrust charges brought by ANDA filer Mutual against patent-holder Tyco. (A … Continue reading →

Posted in Antitrust Issues | Tagged , , , , , , , , | Leave a comment

Ignorance is Bliss – for Teva

Posted on August 4, 2014 by Warren Woessner

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading →

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment

USPTO TRIPs over Myriad-Mayo guidance

Posted on July 31, 2014 by Warren Woessner

Timothy W. Roberts, Chartered Patent Attorney; MA (Oxon); LL.D (honoris causa, Sheffield University) Paul G. Cole,  Chartered Patent Attorney;  MA (Oxon); LLM, NottinghamTrent; Visiting Professor, Bournemouth University The above UK-based European Practitioners have today filed comments at the USPTO arguing … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment